MAIA

#4039
MAIA Biotechnology, Inc. Common Stock
1.3 1 USD
-0.02%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
1.31
1.32
Intervallo Annuale
1.16
2.46
Variazione giornaliera
-1.50%
Variazione Mensile
-10.27%
Variazione di 6 mesi
-12.78%
Variazione Annuale
-37.02%
Chiusura Precedente
1.3 3
Open
1.3 2
Minimo
1.3 1
Massimo
1.3 2
Volume
22
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Quarterly report, Q2 FY2026
MAIA Biotechnology, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
MAIA Biotechnology, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
MAIA Biotechnology, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
MAIA Biotechnology, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
MAIA Biotechnology, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
MAIA Biotechnology, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
MAIA Biotechnology, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
MAIA Biotechnology, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
MAIA Biotechnology, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
MAIA Biotechnology, Inc. current report, Q1 FY2026
8-K

MAIA Biotechnology, Inc. current report, Q1 FY2024

Full document

MAIA Biotechnology, Inc. - Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed by MAIA Biotechnology, Inc. (MAIA) on March 6, 2024, covering events that occurred on March 5, 2024. The Company is a Delaware corporation focused on immuno-oncology cancer treatment candidates and operates as an emerging growth company.

Key Financial Metrics

The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a notification of corporate communications rather than a financial results announcement.

Material Changes

On March 5, 2024, the Company issued a 2024 Letter to Shareholders and a corresponding press release. These documents detail the Company's immuno-oncology cancer treatment candidates and development pipeline. No material changes to financial position or operations were reported in this specific filing.

Guidance, Outlook, and Risks

The filing contains extensive forward-looking statements regarding the Company's future performance. Management cautions that actual results may differ materially from expectations due to various risks, including:

  • The initiation, timing, cost, progress, and results of preclinical and clinical studies.
  • The ability to advance product candidates into and successfully complete clinical studies.
  • The timing or likelihood of regulatory filings and approvals.
  • The ability to develop, manufacture, and commercialize product candidates.
  • Market acceptance and the size/growth potential of target markets.
  • The ability to obtain and maintain intellectual property protection.

The Company explicitly states it undertakes no obligation to publicly update or revise any forward-looking statements except as required by law.

Investor Verification Checklist

  • Review the attached 2024 Letter to Shareholders (Exhibit 99.1) for specific details on the development pipeline.
  • Examine the Press Release dated March 5, 2024 (Exhibit 99.2) for immediate market commentary.
  • Verify the Company's cash runway and burn rate in the most recent 10-Q or 10-K, as this 8-K does not contain financial data.
  • Monitor upcoming clinical trial milestones and regulatory filing dates mentioned in the shareholder letter.

Notizie